我要投票 Sanchine三精在补钙行业中的票数:714
· 外 推 电 报 ·
2026-01-10 16:01:25 星期六

【Sanchine三精是哪个国家的品牌?】

Sanchine三精是什么牌子?「Sanchine三精」是 哈药集团三精制药有限公司 旗下著名品牌。该品牌发源于黑龙江,由创始人芦传有在2015期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力Sanchine三精品牌出海!将品牌入驻外推网,定制Sanchine三精品牌推广信息,可以显著提高Sanchine三精产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

三精制药始建于1950年,初期以生产肌肉和静脉水针剂为主,是黑龙江省最早的专业化生产水针剂和国内最早引进国外水针剂一连机生产设备的企业,是最早通过国家GMP认证的医药企业之一。公司现总占地面积110万平方米,员工总数近6000人,是以OTC产品、处方药与保健食品为主、医药原料和制剂并重的综合性制药企业。2004年,“三精”品牌被国家工商总局认定为“驰名保护”。2011年5月13日,“三精”品牌在“2011中国最有价值品牌评价”中,经权威机构认定,品牌价值为68.93亿元人民币。

目前,三精制药拥有下属子公司15家,其中工业子公司8家、商业子公司5家、其他相关产业子公司2家。截至目前,公司口服液、口服溶液剂、小容量注射剂(非最终灭菌)、冻干粉针剂、片剂、粉针剂、胶囊剂、颗粒剂、合剂、糖浆剂、洗剂、茶剂、散剂13个剂型及无菌原料药(磷霉素钠、炎琥宁)、原料药(拉西地平、盐酸罗沙替丁醋酸酯)均通过2010版GMP认证。其中,口服液剂型产品年生产能力达16亿支。公司主导产品包括葡萄糖酸钙口服溶液、葡萄糖酸锌口服液、双黄连口服液、司乐平片等。近年来,通过药品、保健品的新产品立项研发,不断完善产品线,丰富产品阵容。

六十余年的制药经验,先进的技术设备,一流的管理手段,完善的科研开发体系,使“三精”牌在国内外丰享盛誉。三精一直将产品和服务视为核心竞争力,同时高度重视产品的研发,2004年建成较具规模的研发中心,已成为黑龙江省药物制剂工程技术研究中心、黑龙江省西药制剂重点实验室,承担“十一五”“重大新药创制”科技重大专项——“新型口服缓控释制剂及工艺技术平台”课题和“十二五”“重大新药创制”科技重大专项——“抗阿尔茨海默病药重酒石酸卡巴拉汀及其胶囊的研究开发”课题。2008年,公司成为“国家首批创新型企业”,2012年入选国家火炬计划重点高新技术企业。公司还先后荣获了全国质量管理先进企业、全国守合同重信用企业、全国医药系统优秀企业、全国“五·一劳动奖状”先进集体、“全国企业文化优秀成果奖”、“全国医药行业药品质量诚信建设示范企业”、“21315国际质量信用AAA++级”、“中国优秀诚信企业”、“中国化学制药行业工业企业综合实力百强”企业、黑龙江省“科技创新优秀企业奖”等荣誉称号。

英文翻译:Sanjing pharmaceutical was founded in 1950. At the early stage, it mainly produces muscle and intravenous water injection. It is the first professional enterprise in Heilongjiang Province to produce water injection and the first enterprise in China to introduce foreign water injection production equipment. It is also one of the first pharmaceutical enterprises to pass the national GMP certification. The company now covers an area of 1.1 million square meters and employs nearly 6000 people. It is a comprehensive pharmaceutical enterprise focusing on OTC products, prescription drugs and health food, with equal emphasis on pharmaceutical raw materials and preparations. In 2004, "three fine" brand was recognized as "well-known protection" by the State Administration for Industry and commerce. On May 13, 2011, in the "2011 China's most valuable brand evaluation", the brand value of "three fine" was recognized by the authority as RMB 6.893 billion. At present, Sanjing pharmaceutical has 15 subsidiaries, including 8 Industrial subsidiaries, 5 Commercial subsidiaries and 2 other related industrial subsidiaries. Up to now, 13 dosage forms of the company's oral liquid, oral solution, small volume injection (non final sterilization), freeze-dried powder injection, tablet, powder injection, capsule, granule, mixture, syrup, lotion, tea, powder, sterile API (fosfomycin sodium, Yanhuning), API (lacidipine, rosattidine hydrochloride acetate) have passed GMP certification of 2010 version. Among them, the annual production capacity of oral liquid dosage products reached 1.6 billion. The company's leading products include calcium gluconate oral solution, zinc gluconate oral solution, Shuanghuanglian oral solution, and silepin tablets. In recent years, through the research and development of new products of drugs and health products, the product line has been continuously improved and the product lineup has been enriched. With more than 60 years of pharmaceutical experience, advanced technology and equipment, first-class management means, and perfect scientific research and development system, the "three refined" brand enjoys a good reputation at home and abroad. Sanjing has always regarded products and services as its core competitiveness, and attached great importance to product research and development. In 2004, it established a relatively large-scale research and development center, which has become Heilongjiang pharmaceutical engineering and technology research center and Heilongjiang western pharmaceutical Key Laboratory, undertaking the major science and technology project of "11th Five Year plan" and "major new drug creation" -- new oral sustained and controlled release preparations and technology "Platform" project and "12th Five Year Plan" science and technology major project of "major new drug creation" - research and development of anti Alzheimer's disease drug kabalatin tartrate and its capsule ". In 2008, the company became "the first batch of national innovative enterprises", and in 2012, it was selected as a key high-tech enterprise in the national torch plan. The company has also won the national advanced quality management enterprise, the national contract abiding and trustworthy enterprise, the national excellent pharmaceutical system enterprise, the national advanced collective of "May 1st Labor Award", "national enterprise culture excellent achievement award", "national pharmaceutical industry pharmaceutical quality and integrity construction demonstration enterprise", "21315 International quality and credit AAA + + level", "China excellent and integrity enterprise" "Top 100 enterprises with comprehensive strength in China's chemical and pharmaceutical industry" and "science and technology innovation excellent enterprise award" of Heilongjiang Province, etc.

本文链接: https://www.waitui.com/brand/41c6b1011.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

追觅CES 2026收官:全屋智能生态斩获超50项国际大奖

1月9日,2026年国际消费电子展(CES 2026)在美国拉斯维加斯收官。展会上,追觅科技通过展示多款具身智能创新产品以及50余项全球首创技术,系统呈现其全屋智能生态的最新进展与长期技术路径。凭借在技术研发和产品创新上的持续积淀,追觅斩获了包括CES最高奖“最佳创新奖”,以及由Android Authority、TechRadar、TECHAERIS等多家行业媒体评选的Best of CES 2026奖项在内的超过50余项科技创新大奖,彰显了其产品创新能力及综合实力。

2分钟前

CES 2026收官夜:1200架无人机表演呈现中国企业标识

在2026年国际消费电子展(CES 2026)收官之际,1200架无人机在拉斯维加斯进行了创纪录的灯光表演,并在空中呈现了“36Kr”“Rokid”“同创伟业”等中国企业标识。据了解,本次表演由大漠大提供集群技术支撑,以极简人力实现高强度精准编队,标志着无人机灯光秀已进入可规模化复制的商业新阶段。

2分钟前

马斯克透露特斯拉有大约15万员工,持H-1B签证者不到3000人

一位网友分享美国科技公司雇佣持H-1B签证员工数量的图表,显示特斯拉(445.01, 9.21, 2.11%)雇佣着2908名此类员工,并敦促马斯克在特斯拉裁减持H-1B签证员工的数量。马斯克回应称:“我们这样做绝不是为了省钱。而是为了聘请那些具备专业技能的杰出人才加入我们的团队,而且是以高成本。此外,我们有15万名员工,所以这只是百分之几。”(新浪财经)

2分钟前

雷军:特斯拉确实强,但并非不可战胜

36氪获悉,1月10日,雷军发文称:“看了易车网销量排行榜:特斯拉确实强,但并非不可战胜!我自豪的是,SU7是迄今为止唯一击败Model 3 的同档纯电轿车!出色的产品力和品质,才会有这样的销量。小米YU7,上市仅6个月时间,销量和Model Y 有差距。我相信,假以时日,YU7 也能一较高下!”

2分钟前

外资开年频频加仓中国资产

据上证报,2026年伊始,外资机构对中国资产的配置热情持续升温。记者在港交所披露易检索发现,自2026年1月1日以来,摩根大通在港股密集增持宁德时代、赣锋锂业、信达生物等H股公司,涵盖新能源、生物医药、通信服务等多个领域。“这种现象反映出国际资本对中国经济企稳回升的预期增强,以及港股估值洼地的吸引力凸显,预计2026年内外资机构频频增持的趋势将持续。”一位投行人士对记者表示。此外,2026年以来,景顺中国科技ETF、锐联中国科技创新ETF等多只在美国上市的中国科技类ETF持续吸引资金流入。多家外资巨头认为,中国科技产业长期成长逻辑稳固,中国科技股行情有望在2026年延续。

2分钟前

本页详细列出关于Sanchine三精的品牌信息,含品牌所属公司介绍,Sanchine三精所处行业的品牌地位及优势。
咨询